BioXcel Therapeutics (BTAI) Total Current Liabilities (2017 - 2026)

BioXcel Therapeutics' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $55.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 115.27% year-over-year to $55.0 million in Q1 2026; TTM through Mar 2026 was $55.0 million, a 115.27% increase from a year earlier, with the FY2025 full-year figure at $53.9 million, up 142.55% from the prior year.
• Total Current Liabilities advanced to $55.0 million in Q1 2026 per BTAI's latest filing, from $53.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $55.0 million in Q1 2026 and bottomed at $16.0 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $28.8 million (2023), against an average of $31.5 million.
• Across the five-year window, Total Current Liabilities sank 35.15% in 2024 and soared 142.55% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $32.9 million in 2022, then declined by 17.12% to $27.3 million in 2023, then slipped by 18.46% to $22.2 million in 2024, then surged by 142.55% to $53.9 million in 2025, then gained by 1.98% to $55.0 million in 2026.
• Per Business Quant, the three latest BTAI Total Current Liabilities figures stand at $55.0 million (Q1 2026), $53.9 million (Q4 2025), and $37.8 million (Q3 2025).